CN1331801A - 肾病检测及治疗 - Google Patents
肾病检测及治疗 Download PDFInfo
- Publication number
- CN1331801A CN1331801A CN99814862A CN99814862A CN1331801A CN 1331801 A CN1331801 A CN 1331801A CN 99814862 A CN99814862 A CN 99814862A CN 99814862 A CN99814862 A CN 99814862A CN 1331801 A CN1331801 A CN 1331801A
- Authority
- CN
- China
- Prior art keywords
- disease
- protein
- modified
- albumin
- chromatography
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims description 20
- 208000017169 kidney disease Diseases 0.000 title claims description 14
- 238000000034 method Methods 0.000 claims abstract description 116
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 90
- 210000002700 urine Anatomy 0.000 claims abstract description 83
- 201000010099 disease Diseases 0.000 claims abstract description 76
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 42
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 42
- 102000035118 modified proteins Human genes 0.000 claims abstract 7
- 108091005573 modified proteins Proteins 0.000 claims abstract 7
- 108010088751 Albumins Proteins 0.000 claims description 134
- 102000009027 Albumins Human genes 0.000 claims description 134
- 239000000523 sample Substances 0.000 claims description 56
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 41
- 210000003734 kidney Anatomy 0.000 claims description 38
- 206010012601 diabetes mellitus Diseases 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 26
- 238000003127 radioimmunoassay Methods 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 23
- 208000011580 syndromic disease Diseases 0.000 claims description 19
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 15
- 229940124597 therapeutic agent Drugs 0.000 claims description 11
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 10
- 238000003018 immunoassay Methods 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 238000013399 early diagnosis Methods 0.000 claims description 8
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 230000001154 acute effect Effects 0.000 claims description 7
- 238000001962 electrophoresis Methods 0.000 claims description 7
- 229940088598 enzyme Drugs 0.000 claims description 7
- 230000002132 lysosomal effect Effects 0.000 claims description 7
- 102000006395 Globulins Human genes 0.000 claims description 6
- 108010044091 Globulins Proteins 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- 102000003886 Glycoproteins Human genes 0.000 claims description 5
- 108090000288 Glycoproteins Proteins 0.000 claims description 5
- 102000005686 Serum Globulins Human genes 0.000 claims description 5
- 108010045362 Serum Globulins Proteins 0.000 claims description 5
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims description 5
- 238000004587 chromatography analysis Methods 0.000 claims description 5
- 201000010064 diabetes insipidus Diseases 0.000 claims description 5
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 4
- 206010010356 Congenital anomaly Diseases 0.000 claims description 4
- 206010018372 Glomerulonephritis membranous Diseases 0.000 claims description 4
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 claims description 4
- 208000031814 IgA Vasculitis Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 206010024229 Leprosy Diseases 0.000 claims description 4
- 206010037596 Pyelonephritis Diseases 0.000 claims description 4
- 206010065427 Reflux nephropathy Diseases 0.000 claims description 4
- 208000033626 Renal failure acute Diseases 0.000 claims description 4
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims description 4
- 201000011040 acute kidney failure Diseases 0.000 claims description 4
- 208000012998 acute renal failure Diseases 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 238000005227 gel permeation chromatography Methods 0.000 claims description 4
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 201000006334 interstitial nephritis Diseases 0.000 claims description 4
- 208000009242 medullary sponge kidney Diseases 0.000 claims description 4
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims description 4
- 231100000855 membranous nephropathy Toxicity 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 208000009999 tuberous sclerosis Diseases 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 3
- 108010068307 Alpha-Globulins Proteins 0.000 claims description 3
- 102000002572 Alpha-Globulins Human genes 0.000 claims description 3
- 102000006734 Beta-Globulins Human genes 0.000 claims description 3
- 108010087504 Beta-Globulins Proteins 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 108010075016 Ceruloplasmin Proteins 0.000 claims description 3
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims description 3
- 208000005189 Embolism Diseases 0.000 claims description 3
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims description 3
- 108010049003 Fibrinogen Proteins 0.000 claims description 3
- 102000008946 Fibrinogen Human genes 0.000 claims description 3
- 239000004366 Glucose oxidase Substances 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 108010051696 Growth Hormone Proteins 0.000 claims description 3
- 208000031886 HIV Infections Diseases 0.000 claims description 3
- 208000037357 HIV infectious disease Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 208000008017 Hypohidrosis Diseases 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 102000016943 Muramidase Human genes 0.000 claims description 3
- 108010014251 Muramidase Proteins 0.000 claims description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 3
- 206010028851 Necrosis Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 3
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000004732 Systemic Vasculitis Diseases 0.000 claims description 3
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 3
- 208000001435 Thromboembolism Diseases 0.000 claims description 3
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 3
- 238000005377 adsorption chromatography Methods 0.000 claims description 3
- 238000001042 affinity chromatography Methods 0.000 claims description 3
- 206010002022 amyloidosis Diseases 0.000 claims description 3
- 206010002512 anhidrosis Diseases 0.000 claims description 3
- 230000037001 anhydrosis Effects 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 230000001054 cortical effect Effects 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 238000000151 deposition Methods 0.000 claims description 3
- 201000001981 dermatomyositis Diseases 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 3
- 208000030172 endocrine system disease Diseases 0.000 claims description 3
- 229940012952 fibrinogen Drugs 0.000 claims description 3
- 108010074605 gamma-Globulins Proteins 0.000 claims description 3
- 229940116332 glucose oxidase Drugs 0.000 claims description 3
- 235000019420 glucose oxidase Nutrition 0.000 claims description 3
- 239000000122 growth hormone Substances 0.000 claims description 3
- 208000014951 hematologic disease Diseases 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 238000004255 ion exchange chromatography Methods 0.000 claims description 3
- 238000001155 isoelectric focusing Methods 0.000 claims description 3
- 229960000274 lysozyme Drugs 0.000 claims description 3
- 239000004325 lysozyme Substances 0.000 claims description 3
- 235000010335 lysozyme Nutrition 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 230000017074 necrotic cell death Effects 0.000 claims description 3
- 239000000199 parathyroid hormone Substances 0.000 claims description 3
- 229960001319 parathyroid hormone Drugs 0.000 claims description 3
- 238000004810 partition chromatography Methods 0.000 claims description 3
- 229960001639 penicillamine Drugs 0.000 claims description 3
- 208000023504 respiratory system disease Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 208000007056 sickle cell anemia Diseases 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 201000002859 sleep apnea Diseases 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- 208000011117 substance-related disease Diseases 0.000 claims description 3
- 238000004809 thin layer chromatography Methods 0.000 claims description 3
- 238000007631 vascular surgery Methods 0.000 claims description 3
- 238000007693 zone electrophoresis Methods 0.000 claims description 3
- 206010018374 Glomerulonephritis minimal lesion Diseases 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 208000004883 Lipoid Nephrosis Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 230000005875 antibody response Effects 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 230000008021 deposition Effects 0.000 claims description 2
- 238000001030 gas--liquid chromatography Methods 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 238000004816 paper chromatography Methods 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010051920 Glomerulonephropathy Diseases 0.000 claims 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 2
- 102000004895 Lipoproteins Human genes 0.000 claims 2
- 108090001030 Lipoproteins Proteins 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000002956 necrotizing effect Effects 0.000 claims 2
- 206010000599 Acromegaly Diseases 0.000 claims 1
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 claims 1
- 208000002814 Autosomal Recessive Polycystic Kidney Diseases 0.000 claims 1
- 208000017354 Autosomal recessive polycystic kidney disease Diseases 0.000 claims 1
- 208000025760 Benign familial haematuria Diseases 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 102000001187 Collagen Type III Human genes 0.000 claims 1
- 108010069502 Collagen Type III Proteins 0.000 claims 1
- 208000026372 Congenital cystic kidney disease Diseases 0.000 claims 1
- 206010011732 Cyst Diseases 0.000 claims 1
- 208000015220 Febrile disease Diseases 0.000 claims 1
- 206010018378 Glomerulonephritis rapidly progressive Diseases 0.000 claims 1
- 108010015776 Glucose oxidase Proteins 0.000 claims 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims 1
- 108010062374 Myoglobin Proteins 0.000 claims 1
- 102100030856 Myoglobin Human genes 0.000 claims 1
- 208000000175 Nail-Patella Syndrome Diseases 0.000 claims 1
- 206010029148 Nephrolithiasis Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 102100038803 Somatotropin Human genes 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000003187 abdominal effect Effects 0.000 claims 1
- 238000012084 abdominal surgery Methods 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 229940035674 anesthetics Drugs 0.000 claims 1
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000005637 crescentic glomerulonephritis Diseases 0.000 claims 1
- 208000031513 cyst Diseases 0.000 claims 1
- 208000037828 epithelial carcinoma Diseases 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 229940072221 immunoglobulins Drugs 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000001900 immune effect Effects 0.000 abstract 2
- 210000003712 lysosome Anatomy 0.000 description 54
- 230000001868 lysosomic effect Effects 0.000 description 52
- 206010001580 Albuminuria Diseases 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 20
- 238000009826 distribution Methods 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 230000008569 process Effects 0.000 description 14
- 230000008859 change Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 230000009257 reactivity Effects 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 230000014759 maintenance of location Effects 0.000 description 11
- 208000009928 nephrosis Diseases 0.000 description 11
- 231100001027 nephrosis Toxicity 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 208000007696 Multicystic Dysplastic Kidney Diseases 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 206010027525 Microalbuminuria Diseases 0.000 description 7
- 238000000354 decomposition reaction Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000001542 size-exclusion chromatography Methods 0.000 description 7
- 208000028659 discharge Diseases 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 229940099472 immunoglobulin a Drugs 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- HTSNFXAICLXZMA-CYBMUJFWSA-N 3-[(3s)-1-propylpiperidin-3-yl]phenol Chemical compound C1N(CCC)CCC[C@H]1C1=CC=CC(O)=C1 HTSNFXAICLXZMA-CYBMUJFWSA-N 0.000 description 3
- 102000002734 Collagen Type VI Human genes 0.000 description 3
- 108010043741 Collagen Type VI Proteins 0.000 description 3
- 108700003861 Dominant Genes Proteins 0.000 description 3
- 206010023439 Kidney transplant rejection Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000003923 Protein Kinase C Human genes 0.000 description 3
- 108090000315 Protein Kinase C Proteins 0.000 description 3
- 108700005079 Recessive Genes Proteins 0.000 description 3
- 102000052708 Recessive Genes Human genes 0.000 description 3
- 206010038478 Renal lithiasis Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 3
- 210000000585 glomerular basement membrane Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000004417 patella Anatomy 0.000 description 3
- 229950001815 preclamol Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 description 2
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 208000008748 Lethal Midline Granuloma Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 2
- 206010060880 Monoclonal gammopathy Diseases 0.000 description 2
- 108010061952 Orosomucoid Proteins 0.000 description 2
- 102000012404 Orosomucoid Human genes 0.000 description 2
- 208000002774 Paraproteinemias Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 238000013103 analytical ultracentrifugation Methods 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 206010003230 arteritis Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000007698 birth defect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 208000010932 epithelial neoplasm Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 150000004609 retinol derivatives Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPP7843 | 1998-12-21 | ||
| AUPP7843A AUPP784398A0 (en) | 1998-12-21 | 1998-12-21 | Kidney disease detection and treatment |
| US09/415,217 | 1999-10-12 | ||
| US09/415,217 US6447989B1 (en) | 1998-12-21 | 1999-10-12 | Kidney disease detection and treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1331801A true CN1331801A (zh) | 2002-01-16 |
Family
ID=25645955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN99814862A Pending CN1331801A (zh) | 1998-12-21 | 1999-12-20 | 肾病检测及治疗 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20020012906A1 (enExample) |
| EP (1) | EP1141728B1 (enExample) |
| JP (2) | JP4160263B2 (enExample) |
| CN (1) | CN1331801A (enExample) |
| AT (1) | ATE376187T1 (enExample) |
| AU (1) | AU1674400A (enExample) |
| BR (1) | BR9916407A (enExample) |
| CA (1) | CA2356174A1 (enExample) |
| DE (1) | DE69937368T2 (enExample) |
| DK (1) | DK1141728T3 (enExample) |
| IL (1) | IL143892A0 (enExample) |
| MX (1) | MXPA01006404A (enExample) |
| WO (1) | WO2000037944A1 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104007258A (zh) * | 2013-09-30 | 2014-08-27 | 中国医学科学院基础医学研究所 | 局灶性节段性肾小球硬化的蛋白标志物 |
| CN104849466A (zh) * | 2014-02-14 | 2015-08-19 | 张曼 | 尿液玻璃体结合蛋白在2型糖尿病合并早期肾损伤诊治中的应用 |
| CN107561175A (zh) * | 2017-08-10 | 2018-01-09 | 武汉大学 | 一种肾小球硬化大鼠模型的评价方法 |
| CN110632229A (zh) * | 2019-09-24 | 2019-12-31 | 华兰生物工程重庆有限公司 | 高效液相色谱仪检测静注人免疫球蛋白(pH4)蛋白质含量的方法 |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP784398A0 (en) | 1998-12-21 | 1999-01-21 | Monash University | Kidney disease detection and treatment |
| AU1674400A (en) | 1998-12-21 | 2000-07-12 | Monash University | Kidney disease detection and treatment |
| US7250294B2 (en) * | 2000-05-17 | 2007-07-31 | Geron Corporation | Screening small molecule drugs using neural cells differentiated from human embryonic stem cells |
| AU2002305159B2 (en) * | 2001-03-28 | 2007-12-13 | Heska Corporation | Methods of detecting early renal disease in animals |
| US20030003588A1 (en) * | 2001-06-28 | 2003-01-02 | Comper Wayne D. | Method for kidney disease detection by protein profiling |
| CN100556546C (zh) * | 2003-02-13 | 2009-11-04 | 贝克顿·迪金森公司 | 在血液收集过程中去除成分的装置及其使用 |
| US7482128B2 (en) | 2003-03-27 | 2009-01-27 | Heska Corporation | Anti-feline albumin antibodies |
| JP2007521232A (ja) | 2003-08-08 | 2007-08-02 | アブジェニックス・インコーポレーテッド | 副甲状腺ホルモン（ｐｔｈ）に対する抗体およびその使用 |
| US7318925B2 (en) * | 2003-08-08 | 2008-01-15 | Amgen Fremont, Inc. | Methods of use for antibodies against parathyroid hormone |
| US20050112123A1 (en) * | 2003-10-06 | 2005-05-26 | Vaughan Michael R. | Methods of treating proteinuria |
| US20060286602A1 (en) * | 2004-05-10 | 2006-12-21 | Harald Mischak | Method and markers for the diagnosis of renal diseases |
| JP5785355B2 (ja) * | 2004-11-24 | 2015-09-30 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | 動物における生体異物物質の肝臓クリアランスを改良する方法 |
| US20090176864A1 (en) * | 2004-11-24 | 2009-07-09 | Hill's Pet Nutrition, Inc. | Methods For Improving Hepatic and Immune Function In An Animal |
| US8647660B2 (en) * | 2004-12-29 | 2014-02-11 | Hill's Pet Nutrition, Inc. | Combination of limited nutrients and enhanced dietary antioxidants to impart improved kidney health |
| US8252742B2 (en) | 2004-12-30 | 2012-08-28 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
| CN102907561A (zh) * | 2004-12-30 | 2013-02-06 | 希尔氏宠物营养品公司 | 提高老年动物的生活质量的方法 |
| US20060205818A1 (en) * | 2005-03-08 | 2006-09-14 | Burzynski Stanislaw R | Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives |
| EP1874130A4 (en) * | 2005-04-19 | 2009-04-29 | Hills Pet Nutrition Inc | METHOD AND COMPOSITIONS FOR PREVENTING AND TREATING NURSE DISEASES |
| CA2605855A1 (en) * | 2005-04-29 | 2006-11-09 | Hill's Pet Nutrition, Inc. | Methods for prolonging feline life |
| CA2608670C (en) * | 2005-05-20 | 2019-03-05 | Hill's Pet Nutrition, Inc. | Methods for promoting health or wellness in adult animals |
| WO2007002836A2 (en) * | 2005-06-29 | 2007-01-04 | Hill's Pet Nutrition, Inc. | Methods and compositions for the prevention and treatment of kidney disease |
| CA2619042C (en) * | 2005-08-17 | 2011-03-15 | Hill's Pet Nutrition, Inc. | Methods and compositions for the prevention and treatment of kidney disease |
| AU2008223791B2 (en) * | 2007-03-07 | 2013-10-03 | Mosaiques Diagnostics And Therapeutics Ag | Method for the standardization of the concentration of analytes in a urine sample |
| EP1972940A1 (de) * | 2007-03-14 | 2008-09-24 | mosaiques diagnostics and therapeutics AG | Verfahren und Marker zur Diagnose von Nierenerkrankungen |
| EP2535718B1 (en) * | 2007-05-11 | 2014-07-09 | The Institutes for Pharmaceutical Discovery, LLC | Methods for early diagnosis of kidney disease |
| AU2008309605A1 (en) * | 2007-10-09 | 2009-04-16 | Mosaiques Diagnostics And Therapeutics Ag | Polypeptide marker for the diagnosis of prostate cancer |
| EP2051078A1 (de) * | 2007-10-19 | 2009-04-22 | mosaiques diagnostics and therapeutics AG | Verfahren und Marker zur Diagnose von Diabetes Mellitus |
| JP2011515672A (ja) * | 2008-03-19 | 2011-05-19 | モザイクス ダイアグノスティクス アンド セラピューティクス アーゲー | 腎尿細管の損傷および疾患の診断のための方法およびマーカー |
| EP2313778B1 (en) * | 2008-07-18 | 2015-01-28 | Boston Medical Center Corporation | Diagnostics for membranous nephropathy |
| NZ610356A (en) * | 2008-08-28 | 2015-03-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US9057735B2 (en) * | 2008-08-29 | 2015-06-16 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP2338054A1 (de) * | 2008-09-17 | 2011-06-29 | Mosaiques Diagnostics And Therapeutics AG | Nierenzellkarzinom |
| CN104020284B (zh) * | 2008-10-21 | 2016-08-24 | 阿斯图特医药公司 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
| NZ628843A (en) * | 2008-10-21 | 2016-02-26 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP2913676A1 (en) | 2008-11-10 | 2015-09-02 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| ES2528799T3 (es) * | 2008-11-22 | 2015-02-12 | Astute Medical, Inc. | Métodos para el pronóstico de insuficiencia renal aguda |
| WO2010064239A1 (en) | 2008-12-04 | 2010-06-10 | Technion Research And Development Foundation Ltd. | Apparatus and methods for diagnosing renal disorders |
| BRPI1007483B1 (pt) * | 2009-01-28 | 2021-11-30 | Bio Preventive Medicine Corporation | Método de diagnóstico de nefropatia in vitro, método in vitro para o monitoramento de progresso de nefropatia, método in vitro para o monitoramento da eficácia de um tratamento de nefropatia, método in vitro de avaliação de toxicidade renal de um agente e kit para diagnóstico de nefropatia |
| US9229010B2 (en) | 2009-02-06 | 2016-01-05 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| JP5827226B2 (ja) * | 2009-08-07 | 2015-12-02 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| CN102792161B (zh) * | 2009-08-28 | 2014-11-12 | 阿斯图特医药公司 | 肾损伤和肾衰竭的诊断及预后的方法及组合物 |
| EA201290192A1 (ru) | 2009-11-07 | 2013-02-28 | Астьют Медикал, Инк. | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности |
| MX2012005210A (es) * | 2009-11-07 | 2012-08-03 | Astute Medical Inc | Metodos y composiciones para diagnostico y pronostico de lesion renal y falla renal. |
| JP5763098B2 (ja) | 2009-12-20 | 2015-08-12 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| DK2666872T3 (en) | 2010-02-05 | 2016-07-25 | Astute Medical Inc | Methods and compositions for the diagnosis and prognosis of renal injury and renal insufficiency |
| EP2539712A4 (en) | 2010-02-26 | 2013-09-18 | Astute Medical Inc | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE |
| CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| WO2011162821A1 (en) | 2010-06-23 | 2011-12-29 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US20130203074A1 (en) | 2010-06-23 | 2013-08-08 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| WO2012019110A1 (en) * | 2010-08-05 | 2012-02-09 | Abbott Laboratories | Method and system for managing patient healthcare |
| DE102010038014B4 (de) * | 2010-10-06 | 2021-10-07 | Numares Ag | Verwendung spezifischer Substanzen als Marker zur Bestimmung des Risikos einer Nierenabstoßung |
| KR101215759B1 (ko) | 2010-11-01 | 2012-12-26 | 서울대학교산학협력단 | 오로소뮤코이드를 포함하는 조성물의 용도 |
| PT2691530T (pt) | 2011-06-10 | 2018-05-10 | Univ Oregon Health & Science | Glicoproteínas e vectores recombinantes cmv |
| CN102854325B (zh) * | 2011-07-01 | 2015-01-07 | 复旦大学 | 胰岛素与血清蛋白可逆性结合的亲和力指标测定方法及应用 |
| EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
| US20130115640A1 (en) * | 2011-11-03 | 2013-05-09 | James A. Tumlin | ACTH for Treatment of Kidney Disease |
| WO2013086359A1 (en) | 2011-12-08 | 2013-06-13 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US9689826B2 (en) | 2012-03-11 | 2017-06-27 | Technion Research And Development Foundation Ltd. | Detection of chronic kidney disease and disease progression |
| ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
| CA3158996C (en) | 2013-01-17 | 2024-06-04 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| JP2016188761A (ja) * | 2013-08-23 | 2016-11-04 | 国立研究開発法人国立国際医療研究センター | 糖尿病腎症の発症または発症リスクの検出方法及びキット |
| US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
| EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| CN105917229B (zh) | 2013-12-03 | 2019-04-26 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| US20170205427A1 (en) * | 2014-07-23 | 2017-07-20 | University Of British Columbia | Biomarkers for anderson-fabry disease |
| US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| WO2016164854A1 (en) | 2015-04-09 | 2016-10-13 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| AU2017277305A1 (en) | 2016-06-06 | 2018-12-20 | Astute Medical, Inc. | Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2 |
| US11026625B2 (en) | 2017-08-08 | 2021-06-08 | Fresenius Medical Care Holdings, Inc. | Systems and methods for treating and estimating progression of chronic kidney disease |
| RU2697722C1 (ru) * | 2018-12-06 | 2019-08-19 | Ирина Сергеевна Шатохина | Способ диагностики активности воспалительного процесса при латентном течении хронического пиелонефрита |
| CN111714517A (zh) * | 2020-04-14 | 2020-09-29 | 南开大学 | 一种溶酶体作为制备药物领域的应用 |
| RU2768464C1 (ru) * | 2021-04-27 | 2022-03-24 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации | Способ диагностики мембранозной нефропатии как одной из форм хронического гломерулонефрита |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4994165A (en) * | 1989-02-16 | 1991-02-19 | Cornell Research Foundation, Inc. | Liquid junction coupling for capillary zone electrophoresis/ion spray spectrometry |
| DE69221666T2 (de) | 1991-05-24 | 1998-01-15 | Wakamoto Pharma Co Ltd | Verfahren zur Diagnose von Nierenkrankheiten durch Nachweisung von Albuminfragmenten |
| JPH0682446A (ja) * | 1992-08-31 | 1994-03-22 | Wakamoto Pharmaceut Co Ltd | 腎疾患の診断法 |
| DE4336498A1 (de) * | 1993-10-26 | 1995-04-27 | Bender & Co Gmbh | Verfahren zur Diagnose von Nieren- und Gefäßerkrankungen |
| US5534431A (en) | 1994-02-28 | 1996-07-09 | The Board Of Regents Of The University Of Nebraska | Hybridomas and monoclonal antibodies specific for unique determinants of nephropathy-related immunoglobulin G and complexes thereof |
| US5908925A (en) | 1996-06-27 | 1999-06-01 | Exocell, Inc. | Genetically engineered immunoglobulins with specificity for glycated albumin |
| US5800998A (en) * | 1996-11-12 | 1998-09-01 | Millennium Pharmaceuticals, Inc. | Assays for diagnosing type II diabetes in a subject |
| AU1674400A (en) | 1998-12-21 | 2000-07-12 | Monash University | Kidney disease detection and treatment |
-
1999
- 1999-12-20 AU AU16744/00A patent/AU1674400A/en not_active Abandoned
- 1999-12-20 JP JP2000589950A patent/JP4160263B2/ja not_active Expired - Fee Related
- 1999-12-20 MX MXPA01006404A patent/MXPA01006404A/es not_active IP Right Cessation
- 1999-12-20 EP EP99959616A patent/EP1141728B1/en not_active Expired - Lifetime
- 1999-12-20 BR BR9916407-8A patent/BR9916407A/pt not_active Application Discontinuation
- 1999-12-20 WO PCT/IB1999/002029 patent/WO2000037944A1/en not_active Ceased
- 1999-12-20 DK DK99959616T patent/DK1141728T3/da active
- 1999-12-20 IL IL14389299A patent/IL143892A0/xx unknown
- 1999-12-20 CN CN99814862A patent/CN1331801A/zh active Pending
- 1999-12-20 AT AT99959616T patent/ATE376187T1/de not_active IP Right Cessation
- 1999-12-20 CA CA002356174A patent/CA2356174A1/en not_active Abandoned
- 1999-12-20 DE DE69937368T patent/DE69937368T2/de not_active Expired - Lifetime
-
2001
- 2001-06-28 US US09/893,346 patent/US20020012906A1/en not_active Abandoned
- 2001-06-28 US US09/892,797 patent/US6589748B2/en not_active Expired - Fee Related
-
2003
- 2003-11-26 US US10/721,351 patent/US20040106155A1/en not_active Abandoned
-
2005
- 2005-09-16 JP JP2005270160A patent/JP4388515B2/ja not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104007258A (zh) * | 2013-09-30 | 2014-08-27 | 中国医学科学院基础医学研究所 | 局灶性节段性肾小球硬化的蛋白标志物 |
| CN104007258B (zh) * | 2013-09-30 | 2016-07-06 | 中国医学科学院基础医学研究所 | 局灶性节段性肾小球硬化的蛋白标志物 |
| CN104849466A (zh) * | 2014-02-14 | 2015-08-19 | 张曼 | 尿液玻璃体结合蛋白在2型糖尿病合并早期肾损伤诊治中的应用 |
| CN107561175A (zh) * | 2017-08-10 | 2018-01-09 | 武汉大学 | 一种肾小球硬化大鼠模型的评价方法 |
| CN110632229A (zh) * | 2019-09-24 | 2019-12-31 | 华兰生物工程重庆有限公司 | 高效液相色谱仪检测静注人免疫球蛋白(pH4)蛋白质含量的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006038877A (ja) | 2006-02-09 |
| EP1141728B1 (en) | 2007-10-17 |
| US20020022236A1 (en) | 2002-02-21 |
| JP2002533680A (ja) | 2002-10-08 |
| CA2356174A1 (en) | 2000-06-29 |
| BR9916407A (pt) | 2001-09-25 |
| AU1674400A (en) | 2000-07-12 |
| IL143892A0 (en) | 2002-04-21 |
| JP4160263B2 (ja) | 2008-10-01 |
| DE69937368T2 (de) | 2008-07-17 |
| US20020012906A1 (en) | 2002-01-31 |
| EP1141728A4 (en) | 2005-01-12 |
| DK1141728T3 (da) | 2008-02-04 |
| ATE376187T1 (de) | 2007-11-15 |
| US20040106155A1 (en) | 2004-06-03 |
| WO2000037944A1 (en) | 2000-06-29 |
| EP1141728A1 (en) | 2001-10-10 |
| DE69937368D1 (de) | 2007-11-29 |
| JP4388515B2 (ja) | 2009-12-24 |
| US6589748B2 (en) | 2003-07-08 |
| MXPA01006404A (es) | 2003-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1331801A (zh) | 肾病检测及治疗 | |
| HK1043625A1 (zh) | 腎病檢測及治療 | |
| CN1232826C (zh) | 早期癌症肿瘤标记 | |
| US8859725B2 (en) | Healthy kidney biomarkers | |
| JP4932714B2 (ja) | コペプチンを使用する疾患の診断方法 | |
| US20070087448A1 (en) | Biological profiles and methods of use | |
| CN1520462A (zh) | 通过蛋白质图谱检测肾病的方法 | |
| CN1234118A (zh) | 涉及糖尿病和肥胖症的诊断及治疗的材料与方法 | |
| WO2006015874A2 (en) | Method for diagnosing liver fibrosis | |
| CN1656231A (zh) | 分析样品中非复合形式的前列腺特异抗原以改进前列腺癌检测的方法 | |
| CN1402004A (zh) | 一种免疫层析一步法检测β－肾上腺素激动剂类药物的方法及试纸的制备 | |
| EP1169647B1 (en) | Method for analyzing the amount of intraabdominal adipose tissue | |
| Kawakami et al. | A rapid electrophoretic method for the detection of serum Lp (a) lipoprotein | |
| JP3490715B2 (ja) | ヘモグロビン前進性グルコシル化終末産物の検出方法 | |
| CN101038275A (zh) | 一种分离肝癌α1－抗胰蛋白酶异质体、转铁蛋白异质体的凝集素亲和层析离心柱方法 | |
| CN1145030C (zh) | 测定骨吸收速率的方法 | |
| EP1870708B1 (en) | Method for determining the stage of ulcerative colitis by determining PGE-MUM levels and reagent kit therefore | |
| CN1237346C (zh) | 人髓质素的免疫测定方法以及用该方法诊断多发性硬化 | |
| CN1928564A (zh) | 一种检测Aβ1－42抗体的方法及其试剂盒 | |
| CN1740196A (zh) | 可用于多发性肌炎/皮肌炎诊断的抗原提纯工艺方法及应用 | |
| Sun et al. | Clinical applicability of acid phosphatase isoenzyme assay. | |
| Prabhakaran et al. | Can nutritional criteria help predict outcome in hospitalized patients? | |
| CN1243097C (zh) | 人的细胞间粘附分子－1膜外i－ⅲ功能区基因表达产物及其制备方法和该产物在放免技术中的应用 | |
| CN1763531A (zh) | 氮末端脑利钠肽前体的免疫胶体金的快速定性检测盒 | |
| JP4017326B2 (ja) | 酸化低密度リポタンパク質認識用ぺプチド |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1043625 Country of ref document: HK |